Literature DB >> 4622995

The origin of fibrin breakdown products and the interpretation of their appearance in the circulation.

M J Gallimore, H M Tyler, J T Shaw.   

Abstract

It has been shown that the incubation of human plasma with urokinase at a concentration sufficient to cause rapid lysis of the clots formed on the addition of thrombin does not give rise to the production of measurable concentrations of non-clottable fibrinogen breakdown products. Also, breakdown products could not be detected in the course of experiments in vivo when urokinase was administered to monkeys and only in very low concentrations when a fibrinolytic state was induced by exercise in three healthy human volunteers. In contrast, high concentrations of breakdown products were found after thrombin infusion into monkeys. It is concluded that circulating fibrinogen is not readily broken down into non-clottable products by the fibrinolytic enzymes, and that normal animals and healthy human subjects do not have substantial deposits of fibrin that are available for breakdown during a fibrinolytic episode. The presence of breakdown products in the circulation is therefore likely to be indicative of the fibrinolytic response to an initial coagulation event.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4622995      PMCID: PMC477259          DOI: 10.1136/jcp.25.3.185

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  An immunological method for demonstrating fibrin degradation products in serum and its use in the diagnosis of fibrinolytic states.

Authors:  H C FERREIRA; L G MURAT
Journal:  Br J Haematol       Date:  1963-07       Impact factor: 6.998

2.  Some aspects of fibrin clot lysis and its inhibition by human serum.

Authors:  M J Gallimore; J T Shaw
Journal:  Thromb Diath Haemorrh       Date:  1967-08-15

3.  Detection of fibrinogen degradation products by use of antibody coated latex particles. The possibilities and limits of the method.

Authors:  E J Melliger
Journal:  Thromb Diath Haemorrh       Date:  1970-05-31

4.  A comparative study of four methods for detecting fibrinogen degradation products in patients with various diseases.

Authors:  D P Thomas; S Niewiarowski; A R Myers; K J Bloch; R W Colman
Journal:  N Engl J Med       Date:  1970-09-24       Impact factor: 91.245

5.  Fibrinolytic and defibrinating effect of phenformin plus ethyloestrenol in vivo.

Authors:  G R Fearnley; R Chakrabarti; J F Evans
Journal:  Lancet       Date:  1969-05-03       Impact factor: 79.321

6.  Fibrin degradation products in normal and abnormal pregnancy and parturition.

Authors:  J Bonnar; J F Davidson; C F Pidgeon; G P McNicol; A S Douglas
Journal:  Br Med J       Date:  1969-07-19

7.  The influence of various plasma components on the lysis of dilute human blood clots.

Authors:  M J Gallimore; J T Shaw
Journal:  Thromb Diath Haemorrh       Date:  1969-11-15

8.  Fibrinolytic activity and haemagglutination inhibition immunoassays.

Authors:  J Gormsen
Journal:  Scand J Haematol       Date:  1970

9.  Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment.

Authors:  C Merskey; G J Kleiner; A J Johnson
Journal:  Blood       Date:  1966-07       Impact factor: 22.113

10.  Fibrin degradation products in sera of normal subjects.

Authors:  P C Das; A G Allan; D G Woodfield; J D Cash
Journal:  Br Med J       Date:  1967-12-23
  10 in total
  1 in total

1.  Clinical and laboratory double-blind investigation on effect of fibrinolytic therapy in patients with cutaneous vasculitis.

Authors:  B Dodman; W J Cunliffe; B E Roberts; R Sibbald
Journal:  Br Med J       Date:  1973-04-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.